COGT - Cogent Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$50.00
DETAILS
HIGH:
$60.00
LOW:
$35.00
MEDIAN:
$52.00
CONSENSUS:
$50.00
UPSIDE:
53.05%
About Cogent Biosciences, Inc. (https://www.cogentbio.com)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Andrew R. Robbins | President, Chief Executive Officer & Director | 1976 | $1,321,754 USD |
| Jessica Sachs | Chief Medical Officer | 1975 | $896,623 USD |
| John Edward Robinson | Chief Scientific Officer | 1974 | $868,743 USD |
| John L. Green | Chief Financial Officer & Principal Accounting Officer | 1980 | $834,275 USD |
| Cole Pinnow | Chief Commercial Officer | 1975 | $754,602 USD |
| Abb Hayden | Senior Vice President of Sales | – | – |
| Brad Barnett | Chief Technology Officer | – | – |
| Brad Fell | Senior Vice President of Chemistry | – | – |
| Christi Waarich | Senior Director of Investor Relations | – | – |
| Dana R. Martin | Senior Vice President of Medical Affairs & Chief Patient Officer | – | – |
| Erin Schellhammer | Chief People Officer | – | – |
| Evan D. Kearns | Chief Legal Officer & Corporate Secretary | 1980 | – |
| Rachael Easton | Senior Vice President of Clinical Development | – | – |